- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03914612
Testing av tillegg av immunterapimedisinen Pembrolizumab til vanlig kjemoterapibehandling (paklitaksel og karboplatin) i stadium III-IV eller tilbakevendende endometriekreft
En fase III randomisert, placebokontrollert studie av Pembrolizumab (MK-3475, NSC #776864) i tillegg til paklitaksel og karboplatin for målbart stadium III eller IVA, stadium IVB eller tilbakevendende endometriekreft
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
Studieoversikt
Status
Forhold
- Endometrie klarcellet adenokarsinom
- Endometrielt dedifferensiert karsinom
- Endometrial Endometrioid Adenocarcinoma
- Endometrie blandet celle adenokarsinom
- Endometrial serøst adenokarsinom
- Endometrielt udifferensiert karsinom
- Tilbakevendende endometrieadenokarsinom
- Tilbakevendende endometriekarsinom
- Tilbakevendende endometrielt klarcellet adenokarsinom
- Tilbakevendende endometrielt dedifferensiert karsinom
- Tilbakevendende endometrieendometrioid adenokarsinom
- Tilbakevendende endometrie blandet cellet adenokarsinom
- Tilbakevendende endometrie serøst adenokarsinom
- Tilbakevendende endometrielt udifferensiert karsinom
- Fase III Uterine Corpus Carcinoma eller Carcinosarcoma AJCC V8
- Fase IV livmor corpus carcinoma eller carcinosarcoma ajcc v8
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm.
II. To evaluate blinded independent central review (BICR) assessed or investigator assessed objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by treatment arm and by mismatch repair (MMR) immunohistochemistry (IHC) status in patients who enter the study with measurable disease.
III. To evaluate BICR assessed or investigator assessed duration of response (DOR) by treatment arm and by MMR IHC status in patients who enter the study with measurable disease.
IV. To evaluate the effect of pembrolizumab (MK-3475) on overall survival (OS) in patients with mismatch repair protein proficient (pMMR) or mismatch repair deficiency (dMMR).
V. To determine whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with improved patient reported physical function as measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-physical function scale (short form), quality of life as measured with the Functional Assessment of Cancer Therapy (FACT) - Endometrial Trial Outcome Index (En TOI) and worsened fatigue as measured with the PROMIS-Fatigue scale (short form) in the pMMR patients.
VI. To determine concordance between institutional MMR IHC testing and centralized MMR IHC.
EXPLORATORY OBJECTIVES:
I. To explore the correlation between patient-reported physical function as measured with the PROMIS-physical function scale (short form) and quality of life as measure with the FACT-En TOI.
II. To explore whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with self-reported neurotoxicity as measured with the FACT/Gynecologic Oncology Group Neurotoxicity (GOG-Ntx) subscale (short) and the extent to which patients differ on their self-reported bother from side effects of cancer therapy in the pMMR patients.
III. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer by Programmed Death Ligand 1 (PD-L1) IHC (positive versus [vs] negative).
IV. To assess the association between PD-L1 IHC (positive vs negative) and mismatch repair status (pMMR and dMMR).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I:
COMBINATION PHASE: Patients receive placebo intravenously (IV) over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease may continue treatment for up to a total 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm I will not receive additional placebo infusions.
ARM II:
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo computed tomography (CT) scan throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 6Z8
- The Moncton Hospital
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Royal Victoria Regional Health Centre
-
Greater Sudbury, Ontario, Canada, P3E 5J1
- Health Sciences North
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Oshawa, Ontario, Canada, L1G 2B9
- Lakeridge Health Oshawa
-
Sault Ste. Marie, Ontario, Canada, P6B 0A8
- Algoma District Cancer Program Sault Area Hospital
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Laval, Quebec, Canada, H7M 3L9
- Hopital de la Cite-de-la-Sante
-
Montreal, Quebec, Canada, H2X 3E4
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Women's Cancer Care
-
-
Arizona
-
Goodyear, Arizona, Forente stater, 85338
- CTCA at Western Regional Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Forente stater, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
Little Rock, Arkansas, Forente stater, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Baldwin Park, California, Forente stater, 91706
- Kaiser Permanente-Baldwin Park
-
Bellflower, California, Forente stater, 90706
- Kaiser Permanente-Bellflower
-
Berkeley, California, Forente stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Clovis, California, Forente stater, 93611
- Community Cancer Institute
-
Duarte, California, Forente stater, 91010
- City of Hope Comprehensive Cancer Center
-
Harbor City, California, Forente stater, 90710
- Kaiser Permanente South Bay
-
Irvine, California, Forente stater, 92618
- Kaiser Permanente-Irvine
-
La Jolla, California, Forente stater, 92093
- UC San Diego Moores Cancer Center
-
Lancaster, California, Forente stater, 93534
- City of Hope Antelope Valley
-
Los Angeles, California, Forente stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forente stater, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forente stater, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Los Angeles, California, Forente stater, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Forente stater, 90033
- Los Angeles General Medical Center
-
Mountain View, California, Forente stater, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Oakland, California, Forente stater, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Forente stater, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Forente stater, 92868
- Saint Joseph Hospital - Orange
-
Rancho Mirage, California, Forente stater, 92270
- Eisenhower Medical Center
-
Redding, California, Forente stater, 96001
- Mercy Regional Cancer Center
-
Redding, California, Forente stater, 96002
- Mercy Oncology Center
-
Riverside, California, Forente stater, 92505
- Kaiser Permanente-Riverside
-
Roseville, California, Forente stater, 95661
- Kaiser Permanente-Roseville
-
Sacramento, California, Forente stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Forente stater, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Forente stater, 95816
- Mercy Cancer Center - Sacramento
-
San Diego, California, Forente stater, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Forente stater, 92134
- Naval Medical Center -San Diego
-
San Francisco, California, Forente stater, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Forente stater, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Forente stater, 94115
- California Pacific Medical Center-Pacific Campus
-
San Francisco, California, Forente stater, 94110
- Zuckerberg San Francisco General Hospital
-
San Jose, California, Forente stater, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Forente stater, 94577
- Kaiser Permanente San Leandro
-
San Marcos, California, Forente stater, 92078
- Kaiser Permanente-San Marcos
-
Santa Clara, California, Forente stater, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
South Pasadena, California, Forente stater, 91030
- City of Hope South Pasadena
-
South San Francisco, California, Forente stater, 94080
- Kaiser Permanente-South San Francisco
-
Sunnyvale, California, Forente stater, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Upland, California, Forente stater, 91786
- City of Hope Upland
-
Vallejo, California, Forente stater, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Forente stater, 94596
- Kaiser Permanente-Walnut Creek
-
Walnut Creek, California, Forente stater, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forente stater, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Forente stater, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Forente stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forente stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Forente stater, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Forente stater, 80631
- Banner North Colorado Medical Center
-
Loveland, Colorado, Forente stater, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Forente stater, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
-
Connecticut
-
Danbury, Connecticut, Forente stater, 06810
- Danbury Hospital
-
Guilford, Connecticut, Forente stater, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Forente stater, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, Forente stater, 06102
- Hartford Hospital
-
New Britain, Connecticut, Forente stater, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Forente stater, 06520
- Yale University
-
North Haven, Connecticut, Forente stater, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Norwalk, Connecticut, Forente stater, 06856
- Norwalk Hospital
-
Stamford, Connecticut, Forente stater, 06904
- Stamford Hospital/Bennett Cancer Center
-
Torrington, Connecticut, Forente stater, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Forente stater, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Forente stater, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Forente stater, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Forente stater, 19713
- Helen F Graham Cancer Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- MedStar Washington Hospital Center
-
Washington D.C., District of Columbia, Forente stater, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Bradenton, Florida, Forente stater, 34205
- Florida Cancer Specialists - Bradenton Cancer Center
-
Sarasota, Florida, Forente stater, 34239
- Sarasota Memorial Hospital
-
Sarasota, Florida, Forente stater, 34232
- Florida Cancer Specialists - Sarasota
-
Sarasota, Florida, Forente stater, 34239
- Florida Cancer Specialists - Sarasota Downtown
-
Venice, Florida, Forente stater, 34285
- Florida Cancer Specialists - Venice Island
-
Venice, Florida, Forente stater, 34275
- Florida Cancer Specialists - Venice Pinebrook
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forente stater, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Forente stater, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Forente stater, 30303
- Grady Health System
-
Atlanta, Georgia, Forente stater, 30342
- Northside Hospital
-
Austell, Georgia, Forente stater, 30106
- WellStar Cobb Hospital
-
Fayetteville, Georgia, Forente stater, 30214
- Piedmont Fayette Hospital
-
Gainesville, Georgia, Forente stater, 30501
- Northeast Georgia Medical Center-Gainesville
-
Marietta, Georgia, Forente stater, 30060
- Wellstar Kennestone Hospital
-
Marietta, Georgia, Forente stater, 30060
- WellStar Health System Inc
-
Newnan, Georgia, Forente stater, 30265
- CTCA at Southeastern Regional Medical Center
-
Roswell, Georgia, Forente stater, 30076
- WellStar North Fulton Hospital
-
Savannah, Georgia, Forente stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Forente stater, 31404
- Memorial Health University Medical Center
-
Smyrna, Georgia, Forente stater, 30080
- WellStar Vinings Health Park
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Forente stater, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forente stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forente stater, 60612
- University of Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Forente stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Evanston, Illinois, Forente stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva, Illinois, Forente stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forente stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Harvey, Illinois, Forente stater, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Forente stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
New Lenox, Illinois, Forente stater, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Forente stater, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Forente stater, 60462
- University of Chicago Medicine-Orland Park
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Forente stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Zion, Illinois, Forente stater, 60099
- Midwestern Regional Medical Center
-
-
Indiana
-
Crown Point, Indiana, Forente stater, 46307
- Northwest Cancer Center - Crown Point
-
Dyer, Indiana, Forente stater, 46311
- Northwest Oncology LLC
-
Hobart, Indiana, Forente stater, 46342
- Northwest Cancer Center - Hobart
-
Hobart, Indiana, Forente stater, 46342
- Saint Mary Medical Center
-
Indianapolis, Indiana, Forente stater, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, Forente stater, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Forente stater, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, Forente stater, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, Forente stater, 46256
- Community Cancer Center North
-
Indianapolis, Indiana, Forente stater, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Indianapolis, Indiana, Forente stater, 46312
- Saint Catherine Hospital
-
Mooresville, Indiana, Forente stater, 46158
- Franciscan Health Mooresville
-
Munster, Indiana, Forente stater, 46321
- The Community Hospital
-
Munster, Indiana, Forente stater, 46321
- Women's Diagnostic Center - Munster
-
Valparaiso, Indiana, Forente stater, 46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kansas
-
Fairway, Kansas, Forente stater, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Forente stater, 66160
- University of Kansas Cancer Center
-
Overland Park, Kansas, Forente stater, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood, Kansas, Forente stater, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Edgewood, Kentucky, Forente stater, 41017
- Saint Elizabeth Healthcare Edgewood
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Forente stater, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Forente stater, 70817
- Woman's Hospital
-
Baton Rouge, Louisiana, Forente stater, 70817
- Our Lady of the Lake Medical Oncology
-
Baton Rouge, Louisiana, Forente stater, 70808
- Our Lady of the Lake Physician Group
-
Metairie, Louisiana, Forente stater, 70006
- East Jefferson General Hospital
-
New Orleans, Louisiana, Forente stater, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Forente stater, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, Forente stater, 70115
- Ochsner Baptist Medical Center
-
-
Maine
-
Augusta, Maine, Forente stater, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Forente stater, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Forente stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, Forente stater, 04412
- Lafayette Family Cancer Center-EMMC
-
Rockport, Maine, Forente stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forente stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Forente stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Annapolis, Maryland, Forente stater, 21401
- Luminis Health Anne Arundel Medical Center
-
Baltimore, Maryland, Forente stater, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Forente stater, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Forente stater, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Forente stater, 21201
- University of Maryland/Greenebaum Cancer Center
-
Baltimore, Maryland, Forente stater, 21229
- Saint Agnes Hospital
-
Bel Air, Maryland, Forente stater, 21014
- UM Upper Chesapeake Medical Center
-
Bethesda, Maryland, Forente stater, 20889-5600
- Walter Reed National Military Medical Center
-
Easton, Maryland, Forente stater, 21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Burlington, Massachusetts, Forente stater, 01805
- Lahey Clinic
-
Lowell, Massachusetts, Forente stater, 01854
- Lowell General Hospital
-
Springfield, Massachusetts, Forente stater, 01199
- Baystate Medical Center
-
Winchester, Massachusetts, Forente stater, 01890
- Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
-
Worcester, Massachusetts, Forente stater, 01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Forente stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Flint, Michigan, Forente stater, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Forente stater, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Forente stater, 48503
- Cancer Hematology Centers - Flint
-
Grand Rapids, Michigan, Forente stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Forente stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forente stater, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Forente stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Traverse City, Michigan, Forente stater, 49684
- Munson Medical Center
-
-
Minnesota
-
Bemidji, Minnesota, Forente stater, 56601
- Sanford Joe Lueken Cancer Center
-
Duluth, Minnesota, Forente stater, 55805
- Essentia Health Cancer Center
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Forente stater, 39216
- University of Mississippi Medical Center
-
Jackson, Mississippi, Forente stater, 39202
- Mississippi Baptist Medical Center
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda, Montana, Forente stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forente stater, 59101
- Billings Clinic Cancer Center
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Forente stater, 68198
- University of Nebraska Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Forente stater, 07920
- Memorial Sloan Kettering Basking Ridge
-
Camden, New Jersey, Forente stater, 08103
- Cooper Hospital University Medical Center
-
Lakewood, New Jersey, Forente stater, 08701
- Monmouth Medical Center Southern Campus
-
Livingston, New Jersey, Forente stater, 07039
- Cooperman Barnabas Medical Center
-
Long Branch, New Jersey, Forente stater, 07740
- Monmouth Medical Center
-
Middletown, New Jersey, Forente stater, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Forente stater, 07645
- Memorial Sloan Kettering Bergen
-
Neptune City, New Jersey, Forente stater, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Forente stater, 08903
- Rutgers Cancer Institute of New Jersey
-
Paramus, New Jersey, Forente stater, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Forente stater, 07450
- Neurosurgeons of New Jersey-Ridgewood
-
Ridgewood, New Jersey, Forente stater, 07450
- Valley Health System Ridgewood Campus
-
Somerville, New Jersey, Forente stater, 08876
- Robert Wood Johnson University Hospital Somerset
-
Toms River, New Jersey, Forente stater, 08755
- Community Medical Center
-
Voorhees Township, New Jersey, Forente stater, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
Wayne, New Jersey, Forente stater, 07470
- Valley Medical Group - Wayne Multispecialty Practice
-
Westwood, New Jersey, Forente stater, 07675
- Valley Health System-Hematology/Oncology
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Forente stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Bay Shore, New York, Forente stater, 11706
- Northwell Health Imbert Cancer Center
-
Brightwaters, New York, Forente stater, 11718
- Island Gynecologic Oncology
-
Brooklyn, New York, Forente stater, 11215
- New York-Presbyterian/Brooklyn Methodist Hospital
-
Buffalo, New York, Forente stater, 14263
- Roswell Park Cancer Institute
-
Commack, New York, Forente stater, 11725
- Memorial Sloan Kettering Commack
-
Flushing, New York, Forente stater, 11355
- The New York Hospital Medical Center of Queens
-
Harrison, New York, Forente stater, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, Forente stater, 11042
- Northwell Health/Center for Advanced Medicine
-
Mineola, New York, Forente stater, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Forente stater, 11040
- Long Island Jewish Medical Center
-
New York, New York, Forente stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forente stater, 10029
- Mount Sinai Hospital
-
New York, New York, Forente stater, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Forente stater, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Forente stater, 10011
- Mount Sinai Chelsea
-
New York, New York, Forente stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Forente stater, 14642
- University of Rochester
-
Rochester, New York, Forente stater, 14620
- Highland Hospital
-
Staten Island, New York, Forente stater, 10305
- Staten Island University Hospital
-
Stony Brook, New York, Forente stater, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Forente stater, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Forente stater, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Forente stater, 10467
- Montefiore Medical Center - Moses Campus
-
Uniondale, New York, Forente stater, 11553
- Memorial Sloan Kettering Nassau
-
Valhalla, New York, Forente stater, 10595
- Westchester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Forente stater, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Clinton, North Carolina, Forente stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Concord, North Carolina, Forente stater, 28025
- Atrium Health Cabarrus/LCI-Concord
-
Goldsboro, North Carolina, Forente stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Forente stater, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Forente stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Wilmington, North Carolina, Forente stater, 28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem, North Carolina, Forente stater, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Forente stater, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Forente stater, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forente stater, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Forente stater, 44304
- Summa Health System - Akron Campus
-
Beachwood, Ohio, Forente stater, 44122
- UHHS-Chagrin Highlands Medical Center
-
Canton, Ohio, Forente stater, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South
-
Chardon, Ohio, Forente stater, 44024
- Geauga Hospital
-
Cincinnati, Ohio, Forente stater, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati, Ohio, Forente stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland, Ohio, Forente stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forente stater, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forente stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forente stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forente stater, 43219
- The Mark H Zangmeister Center
-
Mayfield Heights, Ohio, Forente stater, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Forente stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Sylvania, Ohio, Forente stater, 43560
- ProMedica Flower Hospital
-
West Chester, Ohio, Forente stater, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, Forente stater, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forente stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, Forente stater, 97701
- Saint Charles Health System
-
Ontario, Oregon, Forente stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Forente stater, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- Providence Saint Vincent Medical Center
-
Tualatin, Oregon, Forente stater, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, Forente stater, 17822
- Geisinger Medical Center
-
Ephrata, Pennsylvania, Forente stater, 17522
- Ephrata Cancer Center
-
Gettysburg, Pennsylvania, Forente stater, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Forente stater, 17331
- WellSpan Medical Oncology and Hematology
-
Hazleton, Pennsylvania, Forente stater, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Jefferson Hills, Pennsylvania, Forente stater, 15025
- Jefferson Hospital
-
Johnstown, Pennsylvania, Forente stater, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
Lancaster, Pennsylvania, Forente stater, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Forente stater, 17602
- Lancaster General Hospital
-
Lebanon, Pennsylvania, Forente stater, 17042
- Sechler Family Cancer Center
-
Monroeville, Pennsylvania, Forente stater, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Forente stater, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- UPMC-Magee Womens Hospital
-
Pottsville, Pennsylvania, Forente stater, 17901
- Geisinger Cancer Services-Pottsville
-
Scranton, Pennsylvania, Forente stater, 18510
- Community Medical Center
-
West Reading, Pennsylvania, Forente stater, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Forente stater, 15090
- Wexford Health and Wellness Pavilion
-
Wilkes-Barre, Pennsylvania, Forente stater, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
Willow Grove, Pennsylvania, Forente stater, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Forente stater, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Forente stater, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forente stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forente stater, 29601
- Saint Francis Hospital
-
Seneca, South Carolina, Forente stater, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Forente stater, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Forente stater, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Forente stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Forente stater, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Forente stater, 77030
- Houston Methodist Hospital
-
Houston, Texas, Forente stater, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Houston, Texas, Forente stater, 77070
- Methodist Willowbrook Hospital
-
Houston, Texas, Forente stater, 77030
- Ben Taub General Hospital
-
Sugar Land, Texas, Forente stater, 77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, Forente stater, 77385
- Houston Methodist The Woodlands Hospital
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Forente stater, 84106
- University of Utah Sugarhouse Health Center
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Forente stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Gig Harbor, Washington, Forente stater, 98335
- MultiCare Gig Harbor Medical Park
-
Kennewick, Washington, Forente stater, 99336
- Kadlec Clinic Hematology and Oncology
-
Puyallup, Washington, Forente stater, 98372
- MultiCare Good Samaritan Hospital
-
Renton, Washington, Forente stater, 98055
- Valley Medical Center
-
Seattle, Washington, Forente stater, 98122
- Swedish Medical Center-First Hill
-
Tacoma, Washington, Forente stater, 98405
- MultiCare Tacoma General Hospital
-
Vancouver, Washington, Forente stater, 98686
- Legacy Salmon Creek Hospital
-
-
West Virginia
-
Charleston, West Virginia, Forente stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University Healthcare
-
Morgantown, West Virginia, Forente stater, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Burlington, Wisconsin, Forente stater, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown, Wisconsin, Forente stater, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Forente stater, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Forente stater, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Forente stater, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Forente stater, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Forente stater, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Forente stater, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Forente stater, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Medical Center - Minocqua
-
Oconomowoc, Wisconsin, Forente stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Forente stater, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Forente stater, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Forente stater, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Forente stater, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Forente stater, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha, Wisconsin, Forente stater, 53188
- UW Cancer Center at ProHealth Care
-
Wauwatosa, Wisconsin, Forente stater, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Forente stater, 53227
- Aurora West Allis Medical Center
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
-
-
-
-
Saitama, Japan, 350-1298
- Saitama Medical University International Medical Center
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Ehime University Hospital
-
-
Hiroshima
-
Kure, Hiroshima, Japan, 737
- Kure Medical Center and Chugoku Cancer Center
-
-
Niigata
-
Niigata, Niigata, Japan, 951-8520
- Niigata University Medical and Dental Hospital
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
-
-
-
-
Daegu, Sør -Korea, 41404
- Kyungpook National University Chilgok Hospital
-
Seoul, Sør -Korea, 05505
- Asan Medical Center
-
Seoul, Sør -Korea, 06273
- Gangnam Severance Hospital
-
Seoul, Sør -Korea, 120-752
- Yonsei University Health System-Severance Hospital
-
Seoul, Sør -Korea, 139-706
- Korea Cancer Center Hospital
-
-
Daegu
-
Dalseo-gu, Daegu, Sør -Korea, 42601
- Keimyung University-Dongsan Medical Center
-
-
Gyeongsangnam-do
-
Seoul, Gyeongsangnam-do, Sør -Korea, 51353
- Samsung Changwon Hospital
-
-
Kyeonggi-do
-
Seongnam, Kyeonggi-do, Sør -Korea, 463-707
- Seoul National University Bundang Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.
-
Pathology report showing results of institutional MMR IHC testing.
-
Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.).
-
Submission of tumor specimens for centralized MMR IHC testing is required after Step 1 and before Step 2 registration.
-
In patients with measurable disease, lesions will be defined and monitored by RECIST version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.
-
Patients may have received
- NO prior chemotherapy for treatment of endometrial cancer OR
- Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed >= 12 months prior to STEP 2 registration.
-
Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to STEP 2 registration.
-
Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to STEP 2 registration.
-
Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted.
-
Age >= 18.
-
Performance status of 0, 1 or 2.
-
Platelets >= 100,000/mcl.
-
Absolute neutrophil count (ANC) >= 1,500/mcl.
-
Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN).
-
Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled).
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN.
-
Thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal Free T4 level is required.
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 2 registration are eligible for this trial.
-
For patients of child bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
-
Administration of study drugs (pembrolizumab [MK-3475], paclitaxel, carboplatin) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from at least 14 days prior to Step 2 registration (for oral contraceptives), during treatment, and for 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:
- Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
- Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to Step 2 registration; OR
- Have a congenital or acquired condition that prevents childbearing.
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.
Exclusion Criteria:
-
Patients with prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.
-
Patients who have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab (MK-3475) and/or its excipients; and/or a severe hypersensitivity reaction to paclitaxel and/or carboplatin.
-
Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 2 registration.
-
Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Step 2 registration.
- Patients who have received steroids as CT scan contrast premedication may be enrolled.
- The use of inhaled or topical corticosteroids is allowed.
- The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
- The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to Step 2 registration and remain clinically stable.
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease.
-
Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.
-
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.
-
Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
-
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; and cirrhosis.
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Pregnant or lactating patients.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm I (placebo, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions. |
Given IV
Andre navn:
Given IV
Andre navn:
Ancillary studies
Andre navn:
Given IV Ancillary studies Undergo CT scan
Andre navn:
|
|
Eksperimentell: Arm II (pembrolizumab, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. |
Given IV
Andre navn:
Given IV
Andre navn:
Ancillary studies
Andre navn:
Ancillary studies Given IV
Andre navn:
Undergo CT scan
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS)
Tidsramme: Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
|
Progression free survival (PFS) Note: For arm 2 (dMMR Cohort), the point estimate and the upper limit of the confidence interval are not able to be estimated due to insufficient events. |
Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse Events With Grade 3 (or Higher)
Tidsramme: For the adverse event time frame, the interquartile range was (0.79 months, 3.42 months); the maximum was 28.39 months.
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE V5.0). The endpoint is the count of participants with an adverse event of grade 3 (or higher) by treatment group. |
For the adverse event time frame, the interquartile range was (0.79 months, 3.42 months); the maximum was 28.39 months.
|
|
Objective Tumor Response
Tidsramme: For the time frame for tumor response, the interquartile range was (2.27 months, 8.66 months) and the maximum was 36.37 months.
|
Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1. |
For the time frame for tumor response, the interquartile range was (2.27 months, 8.66 months) and the maximum was 36.37 months.
|
|
Duration of Objective Response
Tidsramme: For the duration of objective response, the interquartile range is (4.24 months, 7.92 months); the maximum is 28.68 months.
|
The time difference between the dates of first response and first progression; patients who do not progress are considered censored. Note: for Arm 2 (dMMR Cohort), the upper limit of the confidence interval is not able to be estimated due to an insufficient number of events. |
For the duration of objective response, the interquartile range is (4.24 months, 7.92 months); the maximum is 28.68 months.
|
|
Overall Survival (OS)
Tidsramme: Time from study entry to time of death or the date of last contact, assessed up to 5 years
|
Overall Survival (OS). This endpoint will be assessed by Kaplan-Meier. |
Time from study entry to time of death or the date of last contact, assessed up to 5 years
|
|
Quality of Life (QoL) in pMMR Patients Only
Tidsramme: 0-54 weeks from start of treatment
|
QoL are collected in pMMR patients only and measured with the Function Assessment of Cancer Therapy -Endometrial Trial Outcome Index (FACT En-TOI). The FACT-En TOI scores range 0 - 120 with a larger score suggesting better or favorable state of QOL. |
0-54 weeks from start of treatment
|
|
Concordance Between Institutional Mismatch Repair (MMR) Immunohistochemistry (IHC) Testing and Centralized MMR IHC
Tidsramme: IHC testing values (for both central and institutional) were collected at baseline.
|
Concordance between institutional MMR IHC testing and centralized MMR IHC. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics including the kappa statistic (e.g. Cohen's kappa coefficient). |
IHC testing values (for both central and institutional) were collected at baseline.
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Pembrolizumab Treatment and Self-reported Neurotoxicity
Tidsramme: 0-54 weeks from start of treatment
|
Patient-reported neurotoxicity will be measured with FACT/GOG-Ntx subscale (short form). |
0-54 weeks from start of treatment
|
|
Effect of Pembrolizumab on PFS and OS by Program Death Ligand 1 (PD-L1) IHC
Tidsramme: 5 years
|
Will assess the effect of pembrolizumab on PFS and OS by PD-L1 (combined positive score [CPS]) within proficient MMR (pMMR) and deficient MMR (dMMR) populations. The effectiveness of pembrolizumab will be compared by PD-L1 status (CPS). A formal test will be conducted by examining the interaction term between pembrolizumab treatment (yes or no) with PD-L1 status. The association between PD-L1 CPS status and MMR IHC status will be assessed with odds ratios. A test may be conducted with a Fisher's Exact Test, and confidence intervals will be provided. |
5 years
|
|
Association Between PD-L1 IHC and MMR Status
Tidsramme: 5 years
|
Measures of association between PD-L1 IHC (CPS) and MMR IHC status. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient). |
5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ramez N Eskander, NRG Oncology
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Morton M, Marcu I, Levine M, Cosgrove C, Backes F, O'Malley D, Chambers L. Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma. Obstet Gynecol. 2023 Aug 1;142(2):360-363. doi: 10.1097/AOG.0000000000005243. Epub 2023 Jul 5.
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025 May;31(5):1539-1546. doi: 10.1038/s41591-025-03566-1. Epub 2025 Mar 5.
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27.
- Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024 May;35(5):414-428. doi: 10.1016/j.annonc.2024.02.006. Epub 2024 Feb 29.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Livmorsykdommer
- Kjønnssykdommer, kvinner
- Genitale neoplasmer, kvinnelige
- Uterine neoplasmer
- Sarkom
- Neoplasmer, bindevev og mykt vev
- Neoplasmer, komplekse og blandede
- Endometriale neoplasmer
- Karsinosarkom
- Organiske kjemikalier
- Hydrokarboner
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Koordinasjonskomplekser
- Taxoider
- Cyclodecanes
- Diterpenes
- Helsevesenets økonomi og organisasjoner
- Økonomi
- Karboplatin
- Paclitaxel
- pembrolizumab
- Skatter
Andre studie-ID-numre
- NCI-2019-02186
- U10CA180868 (U.S. NIH-stipend/kontrakt)
- NCI-2019-02186 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- NRG-GY018 (Annen identifikator: CTEP)
- NRG-GY018 (Annen identifikator: NRG Oncology)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .